Outset Medical entered into two senior secured credit facilities with investment affiliates managed by SLR Capital Partners, which collectively provide for borrowings of up to $300 million, comprising up to a $250 million term loan facility and up to a $50 million asset-based revolving credit facility.
Spectrum Pharmaceuticals, a biopharmaceutical company focused on novel and targeted oncology therapies, entered into a five-year debt financing agreement with investment affiliates managed by SLR Capital Partners for a term loan facility of up to $65 million.
SLR Investment Corp. closed its previously announced merger with SLR Senior Investment Corp., with SLR Investment Corp. as the surviving company.
Arcutis Biotherapeutics, a late-stage biopharmaceutical company focused on developing innovations in immuno-dermatology, obtained a $225 million term loan facility from funds managed by SLR Capital Partners.
SLR Investment Corp. (SLRC) and SLR Senior Investment Corp. (SUNS) entered into an agreement to merge together, with SLRC as the surviving company, subject to stockholder approval and customary closing conditions.
SLR Capital Partners closed its healthcare direct lending funds (SLR HCLF), securing more than $480 million in equity commitments and reaching its initial target. With anticipated leverage, total available capital for SLR HCLF is expected to be more than $1 billion.
Phil Guerin, who currently serves as senior partner and head of originations for SLR Capital Partners, was named chief marketing officer of the company. Additionally, Guerin joined SLR Capital Partners’ investment committee.